33 Results for 'Antibiotics'
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
Video/AnimationLight-driven fine chemical production in yeast biohybridsWyss Institute Core Faculty member Neel Joshi explains the concept of yeast biohybrids and how they can be used to harvest energy from light to drive the production of fine chemicals. Credit: Wyss Institute at Harvard University
Video/AnimationDistributed Cell Division CounterGenetically engineered E. coli containing a fluorescing red protein enabled a Wyss Institute and Harvard Medical School team to analyze the population fluctuations of gut microbes by comparing proportion of “marked” to “unmarked” cells. Credit: Wyss Institute at Harvard University
Video/AnimationPathogen-Extracting Sepsis TherapyThis video explains how sepsis induced by an overload of blood pathogens can be treated with the Wyss Institute’s improved pathogen-extracting, spleen-mimicking device. Blood is flown through a cartridge filled with hollow fibers that are coated with a genetically engineered blood protein inspired by a naturally-occurring human molecule called Mannose Binding Lectin (MBL). MBL is...
Video/AnimationGastrointestinal Re-ProgrammingIn this animation, see an example of how genetically engineered microbes being developed by researchers at the Wyss Institute could detect and treat a wide range of gastrointestinal illnesses and conditions. Credit: Wyss Institute at Harvard University
Video/AnimationAntibiotic EfficacyIn this video, Wyss Institute Core Faculty member James Collins and Michael Lobritz explain how antibiotics can have vastly different effects on pathogenic bacteria and suggest potential implications for improving antibiotic treatments in infected patients. Credit: Wyss Institute at Harvard University
Video/AnimationBioinspired Approach to Sepsis TherapyWyss Institute Founding Director Don Ingber, Senior Staff Scientist Michael Super and Technology Development Fellow Joo Kang explain how they engineered the Mannose-binding lectin (MBL) protein to bind to a wide range of sepsis-causing pathogens and then safely remove the pathogens from the bloodstream using a novel microfluidic spleen-like device. Credit: Wyss Institute at Harvard...